Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma

Amish C. Shah*, Jane E. Minturn, Yimei Li, Jean B. Belasco, Peter C. Phillips, Tammy I. Kang, Kristina A. Cole, Angela Jae Waanders, Rosanna Pollack, Concetta Didomenico, Cynthia Wildes, Michael J. Fisher

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: The high prevalence of carboplatin hypersensitivity reactions (HSR) significantly affects the treatment of pediatric patients with low-grade glioma (LGG). Rechallenging patients is an option that must balance the risks of repeat allergic reaction to the benefits of retaining an effective anti-tumor regimen. Procedure: We performed a retrospective review of children with LGG treated with carboplatin and vincristine between October 2000 and April 2013, who had a documented HSR to carboplatin. Patients were re-exposed to carboplatin using either precautionary measures (prolonged infusion time and premedication with H1 antagonists, H2 antagonists, and corticosteroids), a desensitization protocol, or both. Results: We report the results of our institutional experience of carboplatin re-exposure using both premedication with a prolonged infusion time and a desensitization protocol. Overall, 40 of 55 (73%) patients were successfully rechallenged with carboplatin, including 19 of 25 (76%) patients who underwent desensitization. Conclusion: Our results demonstrate re-exposure to be a safe alternative to abandoning carboplatin for patients with a hypersensitivity reaction. We propose a clinical algorithm for treatment.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jan 1 2016


  • Allergic reaction
  • Carboplatin
  • Desensitization
  • Hypersensitivity
  • Low-grade glioma
  • Rechallenge

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma'. Together they form a unique fingerprint.

Cite this